[HTML][HTML] Risk factors for COVID-19 mortality: The effect of convalescent plasma administration
…, PM Carrera Ramos, L Munoz, SA Pesci… - PLoS …, 2021 - journals.plos.org
Background Convalescent plasma, widely utilized in viral infections that induce neutralizing
antibodies, has been proposed for COVID-19, and preliminary evidence shows that it might …
antibodies, has been proposed for COVID-19, and preliminary evidence shows that it might …
Timing of convalescent plasma administration and 28-day mortality in COVID-19 pneumonia
…, PM Carrera Ramos, SA Pesci… - Journal of …, 2022 - journals.sagepub.com
This is a multicenter cohort study including consecutive, hospitalized patients ≥18 years, with
moderate to severe COVID-19, carried out to evaluate the relationship between the timing …
moderate to severe COVID-19, carried out to evaluate the relationship between the timing …
Effect of convalescent plasma on mortality in patients with COVID-19 pneumonia
…, PM Carrera Ramos, L Muñoz, SA Pesci… - medRxiv, 2020 - medrxiv.org
Background Convalescent plasma, widely utilized in viral infections that induce neutralizing
antibodies, has been proposed for COVID-19, and preliminary evidence shows that it might …
antibodies, has been proposed for COVID-19, and preliminary evidence shows that it might …
[HTML][HTML] Effectiveness of BBIBP-CorV, BNT162b2 and mRNA-1273 vaccines against hospitalisations among children and adolescents during the Omicron outbreak in …
…, ANV Baino, L Regairaz, M Salazar, S Pesci… - The Lancet Regional …, 2022 - thelancet.com
Background Although paediatric clinical presentations of COVID-19 are usually less severe
than in adults, serious illness and death have occurred. Many countries started the …
than in adults, serious illness and death have occurred. Many countries started the …
[HTML][HTML] Protection of homologous and heterologous boosters after primary schemes of rAd26-rAd5, ChAdOx1 nCoV-19 and BBIBP-CorV during the omicron outbreak …
…, E Bartel, T Varela, VVG Martínez, S Pesci… - The Lancet Regional …, 2023 - thelancet.com
Background After primary vaccination schemes with rAd26-rAd5 (Sputnik V), ChAdOx1
nCoV-19, BBIBP-CorV or heterologous combinations, the effectiveness of homologous or …
nCoV-19, BBIBP-CorV or heterologous combinations, the effectiveness of homologous or …
EFFECT OF CONVALESCENT PLASMA ON MORTALITY IN PATIENTS WITH COVID-19 PNEUMONIA (preprint)
…, V Gonzalez, PM Carrera, L Muñoz, SA Pesci… - 2020 - pesquisa.bvsalud.org
Abstract Background Convalescent plasma, widely utilized in viral infections that induce
neutralizing antibodies, has been proposed for COVID-19, and preliminary evidence shows that …
neutralizing antibodies, has been proposed for COVID-19, and preliminary evidence shows that …
Affording Immune Checkpoint Inhibitors (ICI) in the treatment of advanced non-small cell lung cancer (NSCLC): Argentinean National Cancer Institute (ANCI) …
C Gabay, S Pesci, J Caldano, MC Diaz - 2020 - ascopubs.org
e19404 Background: ICI agents proved clinical effectiveness in metastatic NSCLC; irrespectively
PDL1 expression, but they increase costs considerably. Thus its cost-effectiveness (CE…
PDL1 expression, but they increase costs considerably. Thus its cost-effectiveness (CE…
Epidemiological and clinical characteristics of non-severe and severe pediatric and adult COVID-19 patients across different geographical regions in the early phase …
PEY Chua, SU Shah, H Gui, J Koh… - Journal of …, 2021 - journals.sagepub.com
This systematic and meta-review aimed to compare clinical presentation, outcomes, and
care management among patients with COVID-19 during the early phase of the pandemic. A …
care management among patients with COVID-19 during the early phase of the pandemic. A …
Serum magnesium levels in hospitalized patients with SARS-CoV-2
Early studies have reported various electrolyte abnormalities at admission in patients with
severe COVID-19. 104 out of 193 patients admitted to our institution presented with …
severe COVID-19. 104 out of 193 patients admitted to our institution presented with …
Timing of Convalescent plasma administration and 28-day mortality for COVID-19 pneumonia.(preprint)
…, N Ferrando, V Gonzalez, PC Ramos, S Pesci… - 2021 - pesquisa.bvsalud.org
Convalescent plasma administration (CPA) is widely used to treat Covid-19, but its effectiveness
remains controversial. Here we report the results of an Expanded Access Program of …
remains controversial. Here we report the results of an Expanded Access Program of …